Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Loading...
Embargo End Date
ICR Authors
Authors
Kottke, T
Evgin, L
Shim, KG
Rommelfanger, D
Boisgerault, N
Zaidi, S
Diaz, RM
Thompson, J
Ilett, E
Coffey, M
Selby, P
Pandha, H
Harrington, K
Melcher, A
Vile, R
Evgin, L
Shim, KG
Rommelfanger, D
Boisgerault, N
Zaidi, S
Diaz, RM
Thompson, J
Ilett, E
Coffey, M
Selby, P
Pandha, H
Harrington, K
Melcher, A
Vile, R
Document Type
Journal Article
Date
2017-11-01
Date Accepted
2017-10-03
Abstract
Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)-mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse. Cancer Immunol Res; 5(11); 1029-45. ©2017 AACR.
Citation
Cancer immunology research, 2017, 5 (11), pp. 1029 - 1045
Source Title
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
2326-6066
eISSN
2326-6074
Research Team
Targeted Therapy
Translational Immunotherapy
Translational Immunotherapy